182 related articles for article (PubMed ID: 1560924)
21. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
Duranteau L; Chanson P; Lavoinne A; Horlait S; Lubetzki J; Kuhn JM
Clin Endocrinol (Oxf); 1991 Jan; 34(1):25-9. PubMed ID: 1672268
[TBL] [Abstract][Full Text] [Related]
22. [Clinical aspects, morphology and biology of prolactinomas after therapy with dopamine agonists. A review of the literature].
Kobras G
Pathologe; 1992 Jul; 13(4):183-9. PubMed ID: 1508856
[No Abstract] [Full Text] [Related]
23. Additional antitumoral effects of bromocriptine and radiotherapy in patients with prolactinomas or acromegaly.
Coculescu M; Alessandrescu D; Stoica T; Simionescu N; Dimitriu V; Oprescu M; Chelmu S; Urba-Navicius V; Isbăşoiu O
Endocrinologie; 1980; 18(4):277-88. PubMed ID: 7209360
[TBL] [Abstract][Full Text] [Related]
24. [Bromocriptine for macroprolactinomas. Discussion of 3 cases treated successfully].
Sapunar J; López JM; Huete I; Tagle R
Rev Med Chil; 1992 Feb; 120(2):168-73. PubMed ID: 1340555
[TBL] [Abstract][Full Text] [Related]
25. Light microscopical morphometry of prolactin secreting adenomas under treatment with dopamine agonists.
Hamester U; Saeger W; Lüdecke DK
Histol Histopathol; 1987 Apr; 2(2):135-42. PubMed ID: 2980713
[TBL] [Abstract][Full Text] [Related]
26. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of prolactin-secreting pituitary tumors with bromocriptine].
Katzir D; Rosenberg T; Ramot Y; Gaver-Shavit A; Gilboa Y
Harefuah; 1990 Feb; 118(3):141-5. PubMed ID: 2341064
[TBL] [Abstract][Full Text] [Related]
28. Combination Treatment with Bromocriptine and Metformin in Patients with Bromocriptine-Resistant Prolactinomas: Pilot Study.
Liu X; Liu Y; Gao J; Feng M; Bao X; Deng K; Yao Y; Wang R
World Neurosurg; 2018 Jul; 115():94-98. PubMed ID: 29530699
[TBL] [Abstract][Full Text] [Related]
29. microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment.
Wang C; Su Z; Sanai N; Xue X; Lu L; Chen Y; Wu J; Zheng W; Zhuge Q; Wu ZB
Oncol Rep; 2012 May; 27(5):1312-20. PubMed ID: 22366961
[TBL] [Abstract][Full Text] [Related]
30. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
Chattopadhyay A; Bhansali A; Masoodi SR
Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
[TBL] [Abstract][Full Text] [Related]
31. [Long-term bromocriptine treatment of giant prolactinoma: report of a case].
Mashio Y; Beniko M; Ikota A; Mizumoto H; Sato S; Yamaguchi O; Suzuki S; Tashiro T; Ikota T
Nihon Naika Gakkai Zasshi; 1989 Dec; 78(12):1785-6. PubMed ID: 2625603
[No Abstract] [Full Text] [Related]
32. Demographic characteristics, presentations and treatment outcome of patients with prolactinoma.
Malik S; Hussain SZ; Basit R; Idress N; Habib A; Zamant M; Islam N
J Ayub Med Coll Abbottabad; 2014; 26(3):269-74. PubMed ID: 25671924
[TBL] [Abstract][Full Text] [Related]
33. Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment.
Saeki N; Nakamura M; Sunami K; Yamaura A
Endocr J; 1998 Aug; 45(4):529-37. PubMed ID: 9881903
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.
Passos VQ; Souza JJ; Musolino NR; Bronstein MD
J Clin Endocrinol Metab; 2002 Aug; 87(8):3578-82. PubMed ID: 12161478
[TBL] [Abstract][Full Text] [Related]
35. [Prolactinoma in man: clinical and histological characteristics].
Trouillas J; Delgrange E; Jouanneau E; Maiter D; Guigard MP; Donckier J; Perrin G; Jan M; Tourniaire J
Ann Endocrinol (Paris); 2000 Sep; 61(3):253-7. PubMed ID: 10970951
[TBL] [Abstract][Full Text] [Related]
36. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
37. [Rhinorrhea and otorrhea: rare complications of the medical treatment in invasive prolactinomas].
Pascal-Vigneron V; Weryha G; Braun M; Morel-Jean J; Bisset S; Leclère J
Ann Endocrinol (Paris); 1994; 54(5):347-51. PubMed ID: 8085783
[TBL] [Abstract][Full Text] [Related]
38. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine.
Lloyd HM; Jacobi JM; Willgoss DA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):79-85. PubMed ID: 7641414
[TBL] [Abstract][Full Text] [Related]
39. The long-term effects of pregnancy and bromocriptine treatment on prolactinomas--the value of radiologic studies.
Badawy SZ; Marziale JC; Rosenbaum AE; Chang JK; Joy SE
Early Pregnancy; 1997 Dec; 3(4):306-11. PubMed ID: 10086082
[TBL] [Abstract][Full Text] [Related]
40. Prolactinomas and resistance to dopamine agonists.
Brue T; Pellegrini I; Priou A; Morange I; Jaquet P
Horm Res; 1992; 38(1-2):84-9. PubMed ID: 1306523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]